Fate Therapeutics Q3 2023: $350M cash, multiple IND clearances, FT522 enrollment started

FATE THERAPEUTICS INC

2023-Q3 EPS reported -$1.19 revenue$61,857,000

Cash, cash equivalents & investments $349.7M as of Sept 30, 2023; runway into 2H25.
Revenue $1.9M from ONO collaboration; GAAP operating expenses $53.2M (R&D $34.3M, G&A $18.9M).
FT522 Phase 1 open for enrollment in B-cell lymphoma; 3-dose cohort at 300M cells per dose.
IND cleared for FT825/ONO-8250 CAR T targeting HER2 in solid tumors; Phase 1 start-up ongoing.
IND cleared for FT819 CAR T in systemic lupus erythematosus; Phase 1 design includes single dose with preconditioning.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-061077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.